Abbott Labs to market Vivus impotence drugs overseas
MOUNTAIN VIEW, Calif., June 19 (Reuters) - Drugmaker Vivus Inc. (NasdaqNM:VVUS - news) announced on Monday a distribution and marketing agreement granting Abbott Laboratories Inc. (NYSE:ABT - news) rights to its impotence drugs Muse and Alibra in select markets, including Europe, Japan, Australia, and South America.
Abbott also has the option to co-develop and license future Vivus transurethral products for the treatment of male erectile dysfunction in those overseas markets.
Muse is a small, single-use disposable plastic applicator that dispenses the drug alprostadil to increase blood flow to the penis. Alibra, a second-generation version of the drug that can be dosed at home, is awaiting regulatory approval in the United States and Europe.
Vivus previously had a pact with AstraZeneca PLC to market Muse, but the British pharmaceutical company withdrew from
the pact last October saying that the April 6, 1999, merger of Astra AB and Zeneca Group PLC to form AstraZeneca led to a change in product strategies.
Vivus markets the drug in the United States, while Muse is approved for marketing in 39 countries.
Excellent news...one way or the other they will be getting monies for an ED drug.
chris
|
